comparemela.com

Latest Breaking News On - National cancer institute combo - Page 1 : comparemela.com

New Trials in Gynecological Cancers Enrolling Now

Early Success With Olaparib Plus Selumetinib Leads to Further Exploration in RAS-mutated Gynecologic Cancers

Shannon N. Westin, MD, MPH, FACOG, shares preclinical data that provided the impetus for the SOLAR trial of olaparib and selumetinib in patients with RAS-mutated gynecologic cancers, key findings from the dose-escalation and -expansion portions of the research, and next steps with the combination.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.